Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Regeneron
Regeneron
Regeneron Antibody Cocktail a Priority for FDA with April Action Date
BioSpace
Fri, 10/15/21 - 12:35 pm
Regeneron
FDA
priority review
COVID-19
antibodies
Regeneron Could Have a Big Catalyst Coming in 2022
Motley Fool
Sat, 10/9/21 - 11:11 pm
Regeneron
Libtayo
cervical cancer
FDA
Sanofi
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race
Fierce Biotech
Mon, 10/4/21 - 11:08 am
JNJ
Xencor
biobucks
Roche
Regeneron
bispecific antibodies
blood cancers
plamotamab
Regeneron's COVID-19 antibody cocktail reduces hospitalization risk by 71%, study shows
Beckers Hospital Review
Sun, 10/3/21 - 08:39 pm
Regeneron
COVID-19
antibodies
Is the cancer immunotherapy market up for disruption as AstraZeneca, Regeneron-Sanofi, cheaper Chinese offerings line up?
Fierce Pharma
Sun, 10/3/21 - 08:27 pm
cancer
oncology
cancer immunotherapy
Merck
AstraZeneca
Regeneron
Sanofi
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
Pharmaforum
Mon, 09/20/21 - 11:07 am
Sanofi
Regeneron
Libtayo
ESMO
non-small cell lung cancer
Merck
Keytruda
Surging US demand triggers new $2.9B purchase of Regeneron's Covid-19 antibodies
Endpoints
Wed, 09/15/21 - 10:47 am
Regeneron
COVID-19
antibodies
government contract
Pfizer's abrocitinib beats blockbuster Dupixent in phase 3 eczema trial, but key questions remain
Fierce Biotech
Mon, 08/30/21 - 11:03 am
Pfizer
abrocitinib
atopic dermatitis
Dupixent
Sanofi
Regeneron
clinical trials
It's back: Eli Lilly's COVID-19 antibody combo makes its return after 2 months on the sidelines
Fierce Pharma
Mon, 08/30/21 - 10:59 am
Eli Lilly
antibodies
COVID-19
Regeneron
GSK
bamlanivimab-etesevimab
Brii gets a Covid-19 antibody boost
EP Vantage
Wed, 08/25/21 - 11:09 am
Brii Biosciences
COVID-19
antibodies
Regeneron
Regeneron earns mid-stage win for higher dose of Eylea, hoping to refresh its sales pitch
Endpoints
Tue, 08/24/21 - 10:51 am
Regeneron
Eylea
clinical trials
wet age-related macular degeneration
Gilead, Regeneron, AstraZeneca and more encourage FDA to expand patient reported outcome guidance
Endpoints
Mon, 08/23/21 - 11:07 am
Gilead Sciences
Regeneron
AstraZeneca
FDA
PROs
oncology
clinical trials
patient-reported outcomes
Novartis says trials back Beovu safety in diabetic eye disease
Pharmaforum
Tue, 08/17/21 - 10:08 am
Novartis
Beovu
diabetic macular edema
Bayer
Regeneron
Eylea
Lilly, swinging at the king, shows Dupixent rival works in phase 3, but wait for key figures goes on
Fierce Biotech
Mon, 08/16/21 - 12:25 pm
Eli Lilly
lebrikizumab
Sanofi
Regeneron
Dupixent
atopic dermatitis
clinical trials
Sanofi and Regeneron solidify Dupixent TV ad lead, topping July pharma spenders again, trailed by AbbVie and Novo Nordisk
Fierce Pharma
Fri, 08/6/21 - 12:22 pm
DTC advertising
television ads
Dupixent
Regeneron
Sanofi
Regeneron drug extends survival in lung cancer trial, lifting company's hopes in field
BioPharma Dive
Thu, 08/5/21 - 11:02 pm
Regeneron
Sanofi
Libtayo
clinical trials
lung cancer
With expanded FDA nod, Regeneron's COVID-19 antibody drug can help the immunocompromised
Fierce Pharma
Mon, 08/2/21 - 10:56 am
Regeneron
FDA
COVID-19
REGEN-COV
Lilly’s lebrikizumab looks to outdo Dupixent
EP Vantage
Mon, 08/2/21 - 10:48 am
Eli Lilly
lebrikizumab
atopic dermatitis
Dupixent
Sanofi
Regeneron
New Drug Proves to Ease the Itch for Chronic Spontaneous Urticaria
BioSpace
Sat, 07/31/21 - 10:18 pm
Regeneron
Sanofi
Dupixent
clinical trials
chronic spontaneous urticaria
FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings
Yahoo/Reuters
Sat, 07/31/21 - 10:11 pm
Regeneron
FDA
COVID-19
Emergency Use Authorization
antibodies
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »